Please login to the form below

Not currently logged in
Email:
Password:

simtuzumab

This page shows the latest simtuzumab news and features for those working in and with pharma, biotech and healthcare.

Boehringer bolsters NASH pipeline with $201m Dicerna deal

Boehringer bolsters NASH pipeline with $201m Dicerna deal

inhibitor acquired from Nimbus in a $1.2bn deal last year, after its lead inhouse drug simtuzumab failed to show efficacy in trials.

Latest news

More from news
Approximately 1 fully matching, plus 13 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Research Partnership

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics